Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
24(S)-HC, 24(S)-OHC, 24(S)OHC, 24OHC24(S)-hydroxycholesterol
2D-LC-IF-MS/MSTwo-dimensional liquid chromatography in-source fragmentation tandem mass spectrometry
4DNPCCSS, 4DNPCSS4-domain composite NPC Clinical Severity Scale
5DNPCCSS, 5DNPCCS5-domain NPC Clinical Severity Scale
7-KC7-ketocholesterol
ABCAdaptive Behavior Composite (Vineland-II)
ABRAuditory brainstem response
ACMGAmerican College of Medical Genetics and Genomics
ADLsActivities of daily living
AE, AEsAdverse event, adverse events
AHFSAmerican Hospital Formulary Service
ANCOVAAnalysis of covariance
ANOAge at neurological onset
ASMDAcid sphingomyelinase deficiency
ASOAntisense oligonucleotide
ATCAnatomical Therapeutic Chemical classification
AUCArea under the curve
AUC0-lastArea under the plasma concentration-time curve from time 0 to the last measurable concentration
AUC8–72Area under the curve from 8 to 72 hours after dosing
AZ-3102Development code for nizubaglustat
BCRPBreast cancer resistance protein
Big4Big Four federal price (Department of Veterans Affairs, Department of Defense, Public Health Service, and Coast Guard)
BSEPBile salt export pump
BTDBreakthrough Therapy Designation
BUNBlood urea nitrogen
C-triolCholestane-3β,5α,6β-triol
CACalifornia
CADCanadian dollars
CAPCapsule
CBMCCerebellomedullary cistern
CCOCoordinated Care Organization
CFRCode of Federal Regulations
CGI-SClinical Global Impression of Severity
CGICClinical Global Impression of Change
CHMPCommittee for Medicinal Products for Human Use
CHUCentre Hospitalier Universitaire (university hospital center)
CIConfidence interval
CI-CSClinical Impression of Change in Severity
CLEARCoordinated lysosomal expression and regulation
CmaxMaximum concentration
CMSCenters for Medicare & Medicaid Services
CNSCentral nervous system
CPTCurrent Procedural Terminology
CRADACooperative research and development agreement
CRISPR/Cas9Clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9
CRLComplete Response Letter
CSFCerebrospinal fluid
CTComputed tomography
CTCAECommon Terminology Criteria for Adverse Events
CVCoefficient of variation
CYPCytochrome P450
DBDouble-blind
dB HLDecibels hearing level
DBSDried blood spot
DCDistrict of Columbia
DDADevelopmental Disabilities Administration
DNADeoxyribonucleic acid
DoDDepartment of Defense
DSCDose selection committee
EAEach (unit of reimbursement)
EAP, EAPsExpanded Access Program, Expanded Access Programs
eGFREstimated glomerular filtration rate
EIEarly infantile (neurological onset form)
EI-NP-CEarly infantile Niemann-Pick disease type C
EMAEuropean Medicines Agency
EPExtension phase
EPAREuropean public assessment report
EQ-5D-3LEuroQol 5-Dimension 3-Level questionnaire
EREndoplasmic reticulum
ERTEnzyme replacement therapy
EUEuropean Union
FABP3Fatty acid binding protein 3
FAMFamily Access Manager
FD&C Act, FDCAFederal Food, Drug, and Cosmetic Act
FDAFood and Drug Administration
FDRFalse discovery rate
FEESFiberoptic endoscopic evaluation of swallowing
FFSFee-for-service
fSARAFunctional Scale for the Assessment and Rating of Ataxia
FSIQFull-Scale IQ
FSSFederal Supply Schedule
GDGestation day
GeMDACGenetic Metabolic Diseases Advisory Committee
GFRGlomerular filtration rate
HCCHepatocellular carcinoma
HCPCSHealthcare Common Procedure Coding System
HCPsHealth care professionals
HDPEHigh-density polyethylene
HGNCHUGO Gene Nomenclature Committee
HPβCD, HP-β-CD, HPBCD, HPB-CD, HP-Beta-CD, HPßCD, 2HPβCD2-hydroxypropyl-beta-cyclodextrin
HRHazard ratio
HRQOL, HRQoLHealth-related quality of life
HSCTHematopoietic stem cell transplantation
HSEM, HSEM-alphaHorizontal saccadic eye movement (velocity)
HSP70Heat shock protein 70
I-NPCInfantile-onset Niemann-Pick disease type C (neurological onset before 6 years of age)
ICC, ICCsIntraclass correlation coefficient, intraclass correlation coefficients
ICD-10-CMInternational Classification of Diseases, Tenth Revision, Clinical Modification
ICERInstitute for Clinical and Economic Review
ICVIntracerebroventricular
IDIntellectually disabled
INDInvestigational new drug (application)
INPDAInternational Niemann-Pick Disease Alliance
INPDRInternational Niemann-Pick Disease Registry
IPR&DIn-process research and development
IQIntelligence quotient
IQRInterquartile range
IRBInstitutional review board
ITIntrathecal
IT-HPBCDIntrathecal 2-hydroxypropyl-beta-cyclodextrin
ITCIsothermal titration calorimetry
IVIntravenous
KMKaplan-Meier
LLCLimited liability company
LP, LPsLumbar puncture, lumbar punctures
LSLeast squares
LTxLiver transplantation
lyso-SMLysosphingomyelin
MATEMultidrug and toxin extrusion protein
MBSImpModified Barium Swallowing Impairment Scale
MDMaryland
MDTMultidisciplinary team
MHRAMedicines and Healthcare products Regulatory Agency
mITTModified intent-to-treat
MMRMMixed model repeated measures
MNARMissing not at random
MRHDMaximum recommended human dose
N/ANot applicable
NADACNational Average Drug Acquisition Cost
NALLN-acetyl-L-leucine
NCATSNational Center for Advancing Translational Sciences
NCINational Cancer Institute
NDANew Drug Application
NDCNational Drug Code
NENot estimable
NfLNeurofilament light chain
NHSNational Health Service
NHxNatural history
NICENational Institute for Health and Care Excellence
NICHDEunice Kennedy Shriver National Institute of Child Health and Human Development
NIHNational Institutes of Health
NIH CCNational Institutes of Health Clinical Center
NIH-PASNational Institutes of Health Penetration-Aspiration Scale
NLGaseNon-lysosomal neutral glucosylceramidase
NP-CNiemann-Pick disease type C
NPCNiemann-Pick disease type C
NPC-002Protocol number of the phase 2/3 trial of arimoclomol
NPC-CSS-1717-domain NPC Clinical Severity Scale
NPC-SINPC Suspicion Index
NPC-SSNPC Severity Scale
NPC1, NPC-1Niemann-Pick disease type C1; NPC intracellular cholesterol transporter 1 (gene and protein)
NPC2Niemann-Pick disease type C2; NPC intracellular cholesterol transporter 2 (gene and protein)
NPCCSS, NPC-CSSNPC Clinical Severity Scale
NPCQLQ-ANPC quality-of-life questionnaire for adults
NPCQLQ-CNPC quality-of-life questionnaire for children
NPDNiemann-Pick disease
NSENeuron-specific enolase
NSSNPC Neurological Severity Score
NVIQNonverbal/Perceptual Reasoning IQ
NYUNew York University
OAEsOtoacoustic emissions
OATOrganic anion transporter
OATPOrganic anion transporting polypeptide
OCTOrganic cation transporter
ODBOntario Drug Benefit
OHCsOuter hair cells
OHPOregon Health Plan
OLOligodendrocyte
OLEOpen-label extension
OLEXOpen-label extension (program)
OMIMOnline Mendelian Inheritance in Man
OPPSOutpatient Prospective Payment System
OROdds ratio
OSOverall survival
P-gp, P-gPP-glycoprotein
PAPrior authorization
PAPPatient Assistance Program
PASPenetration-Aspiration Scale
PBCPublic benefit corporation
PDLPreferred Drug List
PDUFAPrescription Drug User Fee Act
PKPharmacokinetics
PPPer-protocol
PPCSN-palmitoyl-O-phosphocholineserine
PRVPriority review voucher
Q1, Q3First quartile, third quartile (in company timelines, first and third calendar quarter)
Q2WEvery 2 weeks
Q4WEvery 4 weeks
QALYsQuality-adjusted life years
QoL, QOLQuality of life
R4DNPCCSSRescored 4-domain NPC Clinical Severity Scale
RAND-36RAND 36-Item Health Survey
RCTRandomized controlled trial
RHRelative humidity
RP-UPLC-MS/MSReversed-phase ultra-performance liquid chromatography tandem mass spectrometry
RUMCRush University Medical Center
SAE, SAEsSerious adverse event, serious adverse events
SARAScale for the Assessment and Rating of Ataxia
SASStatistical Analysis System (software)
SCSouth Carolina
SCTSafety Concern Threshold
SDStandard deviation
SEStandard error
SEMStandard error of the mean
SMACState Maximum Allowable Cost
SMCScottish Medicines Consortium
sNDASupplemental New Drug Application
SRTSubstrate reduction therapy
t1/2Elimination half-life
TEAE, TEAEsTreatment-emergent adverse event, treatment-emergent adverse events
TFE3Transcription factor E3
TFEBTranscription factor EB
TmaxTime to peak plasma concentration
TXTexas
UCLAUniversity of California, Los Angeles
UKUnited Kingdom
US, U.S., USAUnited States
USDUnited States dollars
USPUnited States Pharmacopeia
VAVeterans Affairs
VdssVolume of distribution at steady state
VFSSVideofluoroscopic swallow study
Vineland-IIVineland Adaptive Behavior Scales, Second Edition
VIQVerbal IQ
VSGPVertical supranuclear gaze palsy
VSSPVertical supranuclear saccadic palsy
VTS-270Development code for adrabetadex (Vtesse)
VTS-270-001Protocol number of the open-label trial of VTS-270 (NCT03643562)
VTS-270-302Protocol number of the 2-participant open-label study of adrabetadex in Costa Rica
VTS301, VTS-301Protocol number of the phase 2b/3 trial of VTS-270 (Parts A and B, NCT02534844; Part C, NCT04958642)
WACWholesale acquisition cost
WRAMLWide Range Assessment of Memory and Learning
YODAYale University Open Data Access (Project)